ReviewNature reviews. Clinical oncology2019
Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer.
Review in Nature reviews. Clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 3 syntheses or guidelines pooled it, 92 citations in OpenAlex.
- Optimal extension time after initial endocrine therapy for postmenopausal hormone receptor-positive early-stage breast cancer: a systematic review and meta-analysis.BMC women's health · 2025Pooled it
- Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis.Breast (Edinburgh, Scotland) · 2021Pooled it
- Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis.Breast cancer research and treatment · 2021Pooled it
- Long-term benefit from adjuvant tamoxifen therapy for ER+ HER2- breast cancer by PR positivity.International journal of cancer · 2026Trial
- Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up.Journal of the National Cancer Institute · 2026Trial
- Progesterone receptor (PR) intra-tumor heterogeneity in premenopausal breast cancer: A secondary analysis of a randomized trial.International journal of cancer · 2026Trial
- Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial.Journal of the National Cancer Institute · 2025Trial
- Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- Optimizing Extended Adjuvant Endocrine Therapy in Early HR+/HER2- Breast Cancer: The Emerging Role of Genomic Assays and ctDNA MRD.Advances in therapy · 2026Review
- "Immune senescence and dormant tumor cells: reconceptualizing breast cancer recurrence as an affliction of aging and chronic inflammation".Annals of medicine and surgery (2012) · 2026Review
- Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling.Nature communications · 2026Article
- Risk of late recurrence of colorectal and breast cancer among older long-term cancer survivors.JNCI cancer spectrum · 2026Article
- Establishment of a model to predict the recurrence time of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.Translational cancer research · 2026Article
- AI-driven CRISPR strategies in breast cancer: Organoid modeling, adaptive editing, and precision delivery.Iranian journal of basic medical sciences · 2026Review
- Subtype-specific genetic drivers of immune evasion in breast cancer.Immuno-oncology technology · 2025Article
- Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studies.The oncologist · 2025Article
- Single Dose of a Small Molecule Leads to Complete Regressions of Large Breast Tumors in Mice.ACS central science · 2025Article
- Secreted LGALS3BP facilitates distant metastasis of breast cancer.Breast cancer research : BCR · 2025Article
- High expression of miR-7974 predicts poor prognosis and is associated with autophagy in estrogen receptor-positive breast cancer.PloS one · 2025Article
- Size and Treatment Outcomes of HR+, HER2- Early Breast Cancer Population With High Risk of Recurrence: A Real-World Cohort Study With Danish Breast Cancer Cooperative Group Registry Data.Journal of health economics and outcomes research · 2025Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Women with early-stage oestrogen receptor (ER)-positive (ER
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.